Akebia Therapeutics, Inc. (AKBA) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Earnings Reports

• Akebia (AKBA) Q1 2026: Vafseo Patient Base Jumps 60% as Observed Dosing Drives Adoption
  May 07, 2026
• Akebia (AKBA) Q4 2025: Vafsio Prescriber Base Expands 5x, Anchoring Dialysis Market Push
  February 26, 2026
• Akebia (AKBA) Q3 2025: Prescribing Access Expands 7x, Setting Up 2026 Inflection
  November 10, 2025
• Akebia (AKBA) Q2 2025: Vafseo Patient Access Doubles, Setting Stage for 275K Prescriber Surge
  August 07, 2025
• Akebia (AKBA) Q1 2025: Vafseo Launch Drives $12M Debut, Setting Up Doubling Patient Access with LDO Rollout
  July 06, 2025
• Akebia (AKBA) Q3 2024: Vafcio Contracts Secure 60% Dialysis Access Ahead of January Launch
  November 07, 2024
• Akebia (AKBA) Q2 2024: 90% Dialysis Market Contracted Ahead of Vafseo Launch
  August 08, 2024
• Akebia (AKBA) Q1 2024: Field Team Expansion Up 55% Accelerates Vafseo Launch Traction
  May 09, 2024

Browse all companies